AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease

Pennisi, Grazia; Enea, Mario; Pandolfo, Alessandra; Ciccioli, Carlo; Infantino, Giuseppe; Parisi, Salvatore; Tulone, Antonio; Marco, V. Di; Craxi, Antonio; Cammà, C.; Petta, S.

doi:10.1016/j.dld.2022.01.033

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondary outcomes included percent TWL, proportion of patients achieving ≥ 7 % and ≥ 10 % TWL, changes in the proportions of patients with portal hypertension and clinically significant portal hypertension, defined as PPG > 5 mmHg and ≥ 10 mmHg, respectively, and changes in noninvasive tests of fibrosis including alanine aminotransferase, aspartate aminotransferase, liver stiffness measurement, controlled-attenuation parameter score 14 , and Fibroscan-AST (FAST) score (a composite score comprising these latter three measurements) 15 16 . Adverse events were graded using the American Society for Gastrointestinal Endoscopy lexicon of adverse events 17 .…”

Section: Methodsmentioning

confidence: 99%

The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

et al. 2023

View full text Add to dashboard Cite

Background and Aims: Goals of therapy for patients with nonalcoholic fatty liver disease (NAFLD) and compensated advanced chronic liver disease (cACLD) include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aims to assess the effect of EGP on PPG. Patients and Methods: In this prospective pilot study, patients with NAFLD and cACLD underwent endoscopic ultrasound-guided PPG determination prior to and at 6 months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing ≥20% reduction in PPG at 6 months. Secondary outcomes included weight loss and changes in non-invasive tests (NITs) of fibrosis. Results: 20 subjects were included. Baseline BMI and liver stiffness measurement were 40.2 [30.1-56.7] kg/m2 and 14.7 [8.2-36] kPa. At 6 months, PPG decreased from 5.4 [0.7-19.6] mmHg to 1.8 [0.4-17.6] mmHg (p=0.002), with 79% (11 out of 14) experiencing ≥20% reduction. Subjects experienced 12.5 [6.5-26.1]% TWL (p = 0.0001) at 6 months, with 89% (17 out of 19) achieving ≥7% and 68% (13 out of 19) achieving ≥10% TWL. There were significant improvements in NITs of fibrosis. Conclusion: Endoscopic gastric plication appears effective at reducing PPG in patients with NAFLD and cACLD.

show abstract

Section: Methodsmentioning

confidence: 99%

The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…To detect advanced fibrosis, among 520 patients with biopsy-proven MASLD, AGILE 3+ yielded an AUROC of 0.88. 47 AGILE 4 does not include age and is focused on detection of cirrhosis. Analysis of FIB-4, VCTE LSM, and AGILE-4 to detect cirrhosis among a French cohort of patients with biopsy-proven MASLD yielded and AUROC of 0.81, 0.88, and 0.89, respectively.…”

Section: Nits To Assess Fibrosis Stage In Masld and Mashmentioning

confidence: 99%

Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease

Tincopa,

Loomba

2024

Semin Liver Dis

View full text Add to dashboard Cite

Risk of disease progression and clinical outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with fibrosis stage and presence of “at-risk metabolic dysfunction-associated steatohepatitis (MASH).” Although liver biopsy is considered the gold standard to diagnose MASH and stage of fibrosis, biopsy is infrequently performed in clinical practice and has associated sampling error, lack of interrater reliability, and risk for procedural complications. Noninvasive tests (NITs) are routinely used in clinical practice for risk stratification of patients with MASLD. Several NITs are being developed for detecting “at-risk MASH” and cirrhosis. Clinical care guidelines apply NITs to identify patients needing subspecialty referral. With recently approved Food and Drug Administration treatment for MASH and additional emerging pharmacotherapy, NITs will identify patients who will most benefit from treatment, monitor treatment response, and assess risk for long-term clinical outcomes. In this review, we examine the performance of NITs to detect “at-risk MASH,” fibrosis stage, response to treatment, and risk of clinical outcomes in MASLD and MASH.

show abstract

“…Die Ultraschall-Elastografie der Leber ist hierfür eine zuverlässige und praktische Methode 10 , wie dies auch von Bauer in dieser Ausgabe gezeigt 6 und daher empfohlen wird. Darüber hinaus tragen die Lebersteifigkeitswerte dazu bei, einen exakten Score für die Prognose der Lebererkrankung zu erstellen 11 . Petta und Kollegen haben jedoch gezeigt, dass ein höherer Grad an Leberfettinfiltration das Risiko erhöht, die mittels Ultraschall-Elastografie gemessene Leberfibrose zu überschätzen 12 und dass eine Kombination von Leberfettquantifizierung und Elastografie das nicht invasive Leber-Staging bei NAFLD-Patienten verbessert 13 .…”

Section: Leberfett-quantifizierung: Brauchen Wir Das?unclassified

“…To this end liver ultrasound elastography methods are reliable and convenient methods 10 , as also shown by Bauer in this issue of the journal 6 and thus recommended. Furthermore, liver stiffness values contribute to build accurate prognostication score for liver disease evolution 11 . However, Petta and colleagues have demonstrated that higher degrees of liver fat infiltration increase the risk of overestimation of liver fibrosis assessed by ultrasound elastography 12 and that the combination of liver fat quantification with elastography makes the non-invasive liver staging in NAFLD patients more accurate 13 .…”

mentioning

confidence: 99%

Liver Fat Quantification: When do We Need It?

Piscaglia¹,

Stefanini²,

Terzi³

et al. 2023

Ultraschall Med

View full text Add to dashboard Cite

AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease

Cited by 5 publications

References 0 publications

The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease

Liver Fat Quantification: When do We Need It?

Contact Info

Product

Resources

About